NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Generic Scrip Share and the Price of Brand-Name Drugs: The Role of the Consumer

John A. Rizzo, Richard Zeckhauser

NBER Working Paper No. 11431
Issued in June 2005
NBER Program(s):   HC   IO

Generic drug utilization has risen dramatically, from 19% of scrips in 1984 to 47% in 2001, thus bringing significant direct dollar savings. Generic drug use may also yield indirect savings if it lowers the average price of those brand-name drugs that are still purchased. Prior work indicates - and we confirm - that generic competition does not induce brand-name producers to lower prices. However, consumer choices between generic and brand-name drugs could affect the average price of those brand-name drugs that are purchased.

We use nationally representative panel data on drug utilization and costs for the years 1996-2001 to examine how the share of an individual's prescriptions filled by generics affects his average out-of-pocket cost for brand-name drugs. Our principal finding is that a higher generic scrip share lowers average brand-name prices to consumers, presumably because consumers are more likely to substitute generics when the price gap is great. This effect is substantial: a 10% increase in the consumer's generic scrip share is associated with a 15.6% decline in the average price he pays for brand-name drugs.

download in pdf format
   (274 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (274 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w11431

Users who downloaded this paper also downloaded these:
Frank and Salkever w5306 "Generic Entry and the Pricing of Pharmaceuticals"
Cook, Hunter, and Vernon w15723 Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures
Berndt and Aitken w16431 Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
Frank and Salkever w3803 Pricing, Patent Loss and the Market For Pharmaceuticals
Berndt, Kyle, and Ling The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us